PHILLIP GULLEY: Open Payments
NPI 1346832854 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,069 in 197 payments from 31 companies in 2025. Trend: 2023 $4,744 · 2024 $4,916 · 2025 $4,069
Food & beverage: $4,040Education: $28
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 25 | $521 |
| UCB, Inc. | 13 | $426 |
| ABBVIE INC. | 25 | $407 |
| Lundbeck LLC | 22 | $376 |
| Celgene Corporation | 18 | $318 |
| Novartis Pharmaceuticals Corporation | 12 | $229 |
| Neurelis, Inc. | 6 | $176 |
| JAZZ PHARMACEUTICALS INC. | 6 | $143 |
| TG Therapeutics, Inc. | 10 | $139 |
| Janssen Biotech, Inc. | 4 | $117 |
Products named: INGREZZA, ZEPOSIA, VYEPTI, KESIMPTA, UBRELVY, QULIPTA, VALTOCO, REXULTI.
Industry payments across TX — which companies pay providers there.
